Literature DB >> 11675408

Renal endothelin-1 and endothelin receptor type B expression in glomerular diseases with proteinuria.

Ingo Lehrke1, Rüdiger Waldherr1, Eberhard Ritz1, Jürgen Wagner1.   

Abstract

The endothelin (ET) system has been studied extensively in experimental models of progressive chronic renal disease, but there is limited information regarding the ET system in renal patients. First, the expression of human ET-1, as well as ET receptor type A (ET-R(A)) and ET-R(B), was studied in 26 renal biopsies from patients with different renal diseases. Gene expression was assessed by quantitative reverse transcription-PCR. Second, ET-1 and ET-R(B) protein expression and localization were examined, by immunohistochemical analyses, among a homogeneous cohort of 16 patients with IgA nephropathy and different degrees of proteinuria. ET-R(B) mRNA expression was threefold higher among patients with higher-grade proteinuria [> or =2 g/24 h, n = 10; OD ratio (ODR), i.e., wild-type/mutant mRNA ratio, 1.81 +/- 0.3], compared with patients with lower-grade proteinuria (<2 g/24 h, n = 8; ODR, 0.63 +/- 0.1; P < 0.01) or control subjects (n = 9; ODR, 0.57 +/- 0.1; P < 0.01). ET-1 gene expression was significantly higher among patients with higher-grade proteinuria, compared with patients with lower-grade proteinuria (P < 0.01) or control subjects (P < 0.05). ET-R(A) mRNA expression was not different among the groups. Patients with higher-grade proteinuria who were receiving angiotensin-converting enzyme inhibitors exhibited significantly (P < 0.05) lower ET-1 and ET-R(B) mRNA expression, which was comparable to that of control subjects. By using immunohistochemical analyses, an association between proteinuria and expression of ET-1 and ET-R(B) in proximal tubular epithelial cells and of ET-1 in glomeruli was confirmed in the separate cohort of patients with IgA nephropathy. It is concluded that the increased ET-R(B) and ET-1 mRNA and protein expression observed in animal models of renal disease is also demonstrable among patients with renal disease and high-grade proteinuria.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11675408     DOI: 10.1681/ASN.V12112321

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  14 in total

1.  Endothelin, nephropathy, and blood pressure.

Authors:  Friedrich C Luft
Journal:  J Mol Med (Berl)       Date:  2002-01-31       Impact factor: 4.599

Review 2.  Endothelin B receptor, a new target in cancer immune therapy.

Authors:  Lana E Kandalaft; Andrea Facciabene; Ron J Buckanovich; George Coukos
Journal:  Clin Cancer Res       Date:  2009-06-30       Impact factor: 12.531

3.  Endothelin receptor antagonists in proteinuric renal disease: every rose has its thorn.

Authors:  Eberhard Ritz; René Wenzel
Journal:  J Am Soc Nephrol       Date:  2010-02-04       Impact factor: 10.121

Review 4.  The role of the kidney in regulating arterial blood pressure.

Authors:  Hani M Wadei; Stephen C Textor
Journal:  Nat Rev Nephrol       Date:  2012-08-28       Impact factor: 28.314

Review 5.  Endothelin-1 gene regulation.

Authors:  Lisa R Stow; Mollie E Jacobs; Charles S Wingo; Brian D Cain
Journal:  FASEB J       Date:  2010-09-13       Impact factor: 5.191

Review 6.  Endothelin-1 and the kidney--beyond BP.

Authors:  Neeraj Dhaun; David J Webb; David C Kluth
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

Review 7.  Autoimmune-mediated renal disease and hypertension.

Authors:  Erika I Boesen; Rahul M Kakalij
Journal:  Clin Sci (Lond)       Date:  2021-09-17       Impact factor: 6.876

8.  Direct action of endothelin-1 on podocytes promotes diabetic glomerulosclerosis.

Authors:  Olivia Lenoir; Marine Milon; Anne Virsolvy; Carole Hénique; Alain Schmitt; Jean-Marc Massé; Yuri Kotelevtsev; Masashi Yanagisawa; David J Webb; Sylvain Richard; Pierre-Louis Tharaux
Journal:  J Am Soc Nephrol       Date:  2014-04-10       Impact factor: 10.121

Review 9.  Endothelin-targeted new treatments for proteinuric and inflammatory glomerular diseases: focus on the added value to anti-renin-angiotensin system inhibition.

Authors:  Ariela Benigni; Simona Buelli; Donald E Kohan
Journal:  Pediatr Nephrol       Date:  2020-03-17       Impact factor: 3.714

10.  Role of endothelin receptor antagonist; bosentan in cisplatin-induced nephrotoxicity in ovariectomized estradiol treated rats.

Authors:  Alieh Zahedi; Mehdi Nematbakhsh; Maryam Moeini; Ardeshir Talebi
Journal:  J Nephropathol       Date:  2015-10-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.